This result is consistent with that previously published by Sakaguchi et al. [26], where the prognosis was unfavorable in NPM1-mut-positive AML cases with low FLT3–ITD AR when allo-HSCT was not carried out in CR1. The gene discussed is NPM1; the disease is acute myeloid leukemia.